MACC1 and ovarian cancer: These findings were consistent with previous reports in patients with ovarian cancer and pancreatic cancer.13, 14 Our results further revealed that patients with MACC1high had an obviously worse survival and a 5‐year survival rate compared with those with MACC1low, and plasma MACC1 was an significant independent prognostic biomarker for CRC patients, strengthening the issue that MACC1 was a novel and reliable molecule in prognostic prediction as earlier studies emphasized.1, 10